Historical development of monoclonal antibody therapeutics.
about
The role and mechanism of exogenous calcitonin gene-related peptide on mesenchymal stem cell proliferation and osteogenetic formation.Human single-chain variable fragment that specifically targets arthritic cartilagePhysiological IgM class catalytic antibodies selective for transthyretin amyloid.Resurrection of a clinical antibody: template proteogenomic de novo proteomic sequencing and reverse engineering of an anti-lymphotoxin-α antibody.Engineering venom's toxin-neutralizing antibody fragments and its therapeutic potential.Structural guided scaffold phage display libraries as a source of bio-therapeutics.Targeted inhibition of TGF-β results in an initial improvement but long-term deficit in force production after contraction-induced skeletal muscle injury.Microbial factories for recombinant pharmaceuticalsAntibody-based therapy of leukaemia.Epidermal growth factor receptor as a therapeutic target in veterinary oncology.Targeted drug delivery for cancer therapy: the other side of antibodies.Clinical management of multiple sclerosis and neuromyelitis optica with therapeutic monoclonal antibodies: approved therapies and emerging candidates.Nebulization as a delivery method for mAbs in respiratory diseases.Monoclonal antibody therapy in multiple sclerosis: critical appraisal and new perspectives.An active murine-human chimeric Fab antibody derived from Escherichia coli, potential therapy against over-expressing VEGFR2 solid tumors.Cloning and expression of the functional human anti-vascular endothelial growth factor (VEGF) using the pcDNA3.1 vector and the human chronic myelogenous leukemia cell line K562.Functional polymorphisms in rhesus macaque FCGRT and β2-m.
P2860
Q31151877-328656EE-B624-40FC-81F9-535E69DD40E1Q33529418-0B3C60C7-7533-430F-B832-14CE4C8AB2EDQ33676625-31C2D014-945A-415A-B652-80D13D1AF2C3Q33804091-D03BE1BE-BF00-42F8-8FC5-413F73F47FBDQ34101828-390CE251-AD2A-400A-851A-1B817548F770Q34946977-9D133F54-1C92-4153-9BDB-F3F3A1EA1C3EQ37093970-AFBB9E31-89C1-4114-A16C-61F5094BFAA4Q37160231-8B1C68CF-EA70-4723-82E7-F24E34FBBA3EQ37605247-371BF1BB-AECB-4FBC-AA5D-FDF7979622C1Q37875223-E4B1FF6B-BA97-41B4-90B8-EB68DBB3B619Q38058816-CA8485ED-7D47-4652-A95D-74E2245A9047Q38286209-1C5057AF-8061-4B2C-9907-EB93B1089F0AQ38306677-ABC18722-0D76-4205-A450-9571F10015A9Q38364547-57BC1A7E-3F5A-417D-B78C-3AE9942DB372Q38410220-2D0B60C7-E88D-4220-914A-DBEDE2FD9783Q39036591-A70AD2D9-5850-4B5E-8F40-62AF16B3AA66Q40091355-BDF6C970-2D84-4433-85DE-0C1412B21FBA
P2860
Historical development of monoclonal antibody therapeutics.
description
2008 nî lūn-bûn
@nan
2008 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2008 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2008年の論文
@ja
2008年論文
@yue
2008年論文
@zh-hant
2008年論文
@zh-hk
2008年論文
@zh-mo
2008年論文
@zh-tw
2008年论文
@wuu
name
Historical development of monoclonal antibody therapeutics.
@ast
Historical development of monoclonal antibody therapeutics.
@en
Historical development of monoclonal antibody therapeutics.
@nl
type
label
Historical development of monoclonal antibody therapeutics.
@ast
Historical development of monoclonal antibody therapeutics.
@en
Historical development of monoclonal antibody therapeutics.
@nl
prefLabel
Historical development of monoclonal antibody therapeutics.
@ast
Historical development of monoclonal antibody therapeutics.
@en
Historical development of monoclonal antibody therapeutics.
@nl
P1476
Historical development of monoclonal antibody therapeutics.
@en
P2093
Chernajovsky Y
P356
10.1007/978-3-540-73259-4_1
P577
2008-01-01T00:00:00Z